Latest News

The 2022 National Drug Control Strategy was released on April 21, 2022. Over the course of a year, it was developed through requests for written consultations from more than 2,000 external stakeholders, including the entirety of the U.S. Congress; all 50 Governors; and hundreds of advocates representing law enforcement, public health, and Tribal communities. This new Strategy…

April 12, 2022: The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has reviewed the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Key updates are summarized below: The U.S. Food and Drug Administration (FDA) recently approved long-acting injectable cabotegravir and rilpivirine (Cabenuva) for use in children and…

February 7, 2022:  The COVID-19 Treatment Guidelines Panel (the Panel) has published a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. The Panel periodically publishes statements that provide up-to-date guidance for clinicians on various aspects of COVID-19 treatment. During this update, the information and recommendations from several recently published statements were incorporated into the…

February 17, 2022: The Panel updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Highlights from the updated section are summarized below:  Mycobacterium tuberculosis Updated references and rationales. Updated drug–drug interactions. Recommended short-course, rifamycin-based, latent tuberculosis infection (LTBI) treatment regimens (3HP and 3HR) over longer isoniazid monotherapy. Clarified that, for the…

On December 10, 2021, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. Apretude is given first as two initiation injections administered one month apart, and then every…

January 5, 2022: The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission recently updated several sections of the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. The following sections were among those updated: Maternal HIV Testing and Identification of Perinatal…

This notice updates and corrects an announcement on this subject sent January 20, 2022. The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) updated the following sections of the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Highlights are summarized below: Early (Acute and Recent) HIV Infection…

December 8, 2021: Today, the Centers for Disease Control and Prevention (CDC) published its updated Clinical Practice Guideline for Preexposure Prophylaxis for HIV Prevention and Clinical Providers Supplement. The updated guideline and supplement reflect the latest science and are intended to help physicians effectively prescribe all FDA-approved pre-exposure prophylaxis (PrEP) medications to patients and increase PrEP use among all…

November 18, 2021: The Panel updated the following sections of the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Highlights from the sections are summarized below:  Appendix B: Panel Roster and Financial Disclosures:   Updated member conflict of interest information for 2021-2022.Updated roster to include 22 new members, 6 new Section…